PDGFRB and idiopathic interstitial pneumonia: Furthermore, Nintedanib, an approved antifibrotic treatment for IPF, is a small molecule inhibitor against receptor tyrosine kinases such as PDGFR (52), which inhibits fibroblast proliferation and differentiation and ECM production in vitro.